Previous 10 | Next 10 |
DURECT ([[DRRX]] -15.5%) priced its earlier announced underwritten public offering of 17.7M shares for gross proceeds of ~$42.5M.Underwriters granted 30-day option to to purchase up to an additional 2.66M shares.Proceeds to be used for general corporate purposes, which may include clinical tr...
DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock PR Newswire CUPERTINO, Calif. , Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatme...
DURECT (DRRX) slumped 10.8% in after hours trade after it commenced an underwritten public offering with underwriters granted 30-day option to purchase up to an additional 15% of the number of shares.Offer size, terms not yet disclosed. For further details see: DURECT und...
DURECT Corporation Announces Proposed Offering of Common Stock PR Newswire CUPERTINO, Calif. , Feb. 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injur...
Artelo Biosciences (ARTL) +78%.Moleculin Biotech (MBRX) +49% on announcing 100% survival achieved in Osteosarcoma Lung Metastases Animal Model.DURECT (DRRX) +42% after FDA approval for Posimir.Holicity (HOLUU) +38% on plan to take rocket maker Astra public.Tiziana Life Sciences...
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression POSIMIR is the only approved sustained-release bupivacaine product indicated for up to 72 hours of post-surgical a...
DURECT Corporation (DRRX) has gained ~33.3% in premarket trading after the FDA greenlighted the company’s postoperative pain relief depot product POSIMIR. The company has yet to issue an official statement.In January, DURECT announced the outcome of an FDA Advisory ...
DURECT ([[DRRX]] +3.6%) has dosed the first patient in its AHFIRM Phase 2b study evaluating its lead candidate, DUR-928 in severe alcohol-associated hepatitis ((AH)) patients.In this placebo-controlled 300-subject study, the company will evaluate 90-day survival rate for patients treated...
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis PR Newswire CUPERTINO, Calif. , Jan. 25, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first ...
DURECT Corporation Appoints Two New Board Members PR Newswire CUPERTINO, Calif. , Jan. 5, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the appointment of two new members to its board of directors, Gail J. Maderis , MBA and Moha...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...